DEF 14A: Windtree Therapeutics Seeks Stockholder Approval for Reverse Stock Split and Increased Equity Incentive Plan

Windtree Therapeutics is asking stockholders to approve a reverse stock split and an increase in the number of shares available under its equity incentive plan at a special meeting on February 3, 2025.

Summary

• Windtree Therapeutics is holding a special meeting of stockholders on February 3, 2025, to vote on three proposals.
• The first proposal is to approve an amendment to the company's charter to effect a reverse stock split of its common stock at a ratio between 1-for-5 and 1-for-50, with the specific ratio and timing to be determined by the Board of Directors.
• The second proposal is to approve an amendment to the Amended and Restated 2020 Equity Incentive Plan to increase the number of shares authorized for issuance from 41,010 to 1,141,010.
• The third proposal is to approve the adjournment of the special meeting if there are insufficient votes to approve the other proposals or to establish a quorum.
• The Board of Directors recommends voting in favor of all three proposals.
• The record date for determining stockholders eligible to vote at the special meeting was December 20, 2024.
• The company had 11,048,828 shares of common stock outstanding on the record date.

Sentiment

Score: 6

Explanation: The document is neutral to slightly positive. While it addresses the need to regain Nasdaq compliance and incentivize employees, it also acknowledges the risks associated with a reverse stock split. The Board's recommendation to vote for the proposals suggests a belief in their potential benefits.

Positives

• The reverse stock split aims to increase the stock price to meet Nasdaq's minimum bid price requirement and potentially attract a broader range of investors.
• Increasing the shares available under the equity incentive plan will help the company attract, motivate, and retain key employees and directors.
• The company's three-year average burn rate for equity awards is below the industry threshold.
• The Board believes the reverse stock split will improve the perception of the company's common stock as a viable investment security.

Negatives

• The reverse stock split may not increase the stock price over the long term.
• The reverse stock split may decrease the liquidity of the company's common stock.
• Some stockholders may end up owning odd lots, which can be more difficult to sell.
• The reverse stock split could lead to a decrease in the company's overall market capitalization.
• Failure to approve the reverse stock split could result in delisting from the Nasdaq Stock Market.

Risks

• The reverse stock split may not achieve the desired increase in stock price or maintain compliance with Nasdaq listing requirements.
• Delisting from Nasdaq could negatively impact the liquidity and market price of the company's common stock, as well as its ability to raise capital.
• If the Board authorizes the issuance of additional shares subsequent to the Reverse Split, the dilution to the ownership interest of our existing stockholders may be greater than would occur had the Reverse Split not been effected.

Future Outlook

The company hopes that the reverse stock split will help it regain compliance with Nasdaq listing requirements and attract a broader range of investors. The company expects that the total number of shares available under the Amendment, if approved, would meet our equity compensation needs for approximately the next two years.

Management Comments

• The Board believes that effecting the Reverse Split would increase the price of our Common Stock which would, among other things, help us to meet certain continued listing requirements of the Nasdaq Capital Market; appeal to a broader range of investors to generate greater interest in the Company; and improve perception of our Common Stock as an investment security.
• The Board believes that stockholder approval of a range of potential Reverse Split ratios is in the best interests of our Company and stockholders because it is not possible to predict market conditions at the time the Reverse Split would be implemented.

Industry Context

Reverse stock splits are a common strategy for companies facing delisting from exchanges due to low share prices. Increasing equity incentive plans is also a common practice to remain competitive in attracting and retaining talent, especially in the biotech industry.

Comparison to Industry Standards

• Many biotech companies with low share prices have implemented reverse stock splits to maintain their Nasdaq listing, such as BioPharmX, which implemented a 1-for-20 reverse stock split in 2019.
• The three-year average burn rate of 2.25% is below the ISS industry category burn rate threshold of 7.39%.
• Increasing the share pool for equity compensation is a standard practice in the biotech industry to attract and retain talent, similar to how companies like Amgen and Gilead use stock options and RSUs as a significant part of their compensation packages.

Stakeholder Impact

• Shareholders may experience a change in the number of shares they own due to the reverse stock split.
• Employees and directors may benefit from the increased availability of equity awards.
• The company's ability to attract and retain talent could be enhanced by the increased equity incentive plan.
• The company's listing status on Nasdaq could be affected by the outcome of the vote on the reverse stock split.

Next Steps

• Stockholders to vote on the proposals at the Special Meeting on February 3, 2025.
• The Board to determine whether to implement the reverse stock split and, if so, the specific ratio.
• The company to file a Certificate of Amendment with the Secretary of State of Delaware if the reverse stock split is approved and implemented.
• The company to attend a hearing before the Nasdaq Hearings Panel on February 4, 2025.

Key Dates

Keywords

reverse stock split, equity incentive plan, proxy statement, stockholders meeting, Nasdaq, common stock, Windtree Therapeutics